339 related articles for article (PubMed ID: 22939618)
1. Single-stranded siRNAs activate RNAi in animals.
Lima WF; Prakash TP; Murray HM; Kinberger GA; Li W; Chappell AE; Li CS; Murray SF; Gaus H; Seth PP; Swayze EE; Crooke ST
Cell; 2012 Aug; 150(5):883-94. PubMed ID: 22939618
[TBL] [Abstract][Full Text] [Related]
2. 5'-(E)-Vinylphosphonate: A Stable Phosphate Mimic Can Improve the RNAi Activity of siRNA-GalNAc Conjugates.
Parmar R; Willoughby JL; Liu J; Foster DJ; Brigham B; Theile CS; Charisse K; Akinc A; Guidry E; Pei Y; Strapps W; Cancilla M; Stanton MG; Rajeev KG; Sepp-Lorenzino L; Manoharan M; Meyers R; Maier MA; Jadhav V
Chembiochem; 2016 Jun; 17(11):985-9. PubMed ID: 27121751
[TBL] [Abstract][Full Text] [Related]
3. 5΄-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo.
Haraszti RA; Roux L; Coles AH; Turanov AA; Alterman JF; Echeverria D; Godinho BMDC; Aronin N; Khvorova A
Nucleic Acids Res; 2017 Jul; 45(13):7581-7592. PubMed ID: 28591791
[TBL] [Abstract][Full Text] [Related]
4. Identification of metabolically stable 5'-phosphate analogs that support single-stranded siRNA activity.
Prakash TP; Lima WF; Murray HM; Li W; Kinberger GA; Chappell AE; Gaus H; Seth PP; Bhat B; Crooke ST; Swayze EE
Nucleic Acids Res; 2015 Mar; 43(6):2993-3011. PubMed ID: 25753666
[TBL] [Abstract][Full Text] [Related]
5. Relative Quantification of siRNA Strand Loading into Ago2 for Design of Highly Active siRNAs.
Angart PA; Adu-Berchie K; Carlson RJ; Vocelle DB; Chan C; Walton SP
Methods Mol Biol; 2019; 1974():41-56. PubMed ID: 31098994
[TBL] [Abstract][Full Text] [Related]
6. siRNA carrying an (E)-vinylphosphonate moiety at the 5΄ end of the guide strand augments gene silencing by enhanced binding to human Argonaute-2.
Elkayam E; Parmar R; Brown CR; Willoughby JL; Theile CS; Manoharan M; Joshua-Tor L
Nucleic Acids Res; 2017 Apr; 45(6):3528-3536. PubMed ID: 27903888
[TBL] [Abstract][Full Text] [Related]
7. Induction of RNAi Responses by Short Left-Handed Hairpin RNAi Triggers.
Hagopian JC; Hamil AS; van den Berg A; Meade BR; Eguchi A; Palm-Apergi C; Dowdy SF
Nucleic Acid Ther; 2017 Oct; 27(5):260-271. PubMed ID: 28933656
[TBL] [Abstract][Full Text] [Related]
8. Competition potency of siRNA is specified by the 5'-half sequence of the guide strand.
Yoo JW; Kim S; Lee DK
Biochem Biophys Res Commun; 2008 Feb; 367(1):78-83. PubMed ID: 18164261
[TBL] [Abstract][Full Text] [Related]
9. Conversion of pre-RISC to holo-RISC by Ago2 during assembly of RNAi complexes.
Kim K; Lee YS; Carthew RW
RNA; 2007 Jan; 13(1):22-9. PubMed ID: 17123955
[TBL] [Abstract][Full Text] [Related]
10. The 5' binding MID domain of human Argonaute2 tolerates chemically modified nucleotide analogues.
Deleavey GF; Frank F; Hassler M; Wisnovsky S; Nagar B; Damha MJ
Nucleic Acid Ther; 2013 Feb; 23(1):81-7. PubMed ID: 23289589
[TBL] [Abstract][Full Text] [Related]
11. siRNA potency enhancement via chemical modifications of nucleotide bases at the 5'-end of the siRNA guide strand.
Shinohara F; Oashi T; Harumoto T; Nishikawa T; Takayama Y; Miyagi H; Takahashi Y; Nakajima T; Sawada T; Koda Y; Makino A; Sato A; Hamaguchi K; Suzuki M; Yamamoto J; Tomari Y; Saito JI
RNA; 2021 Feb; 27(2):163-173. PubMed ID: 33177188
[TBL] [Abstract][Full Text] [Related]
12. Investigation of Strand-Selective Interaction of SNA-Modified siRNA with AGO2-MID.
Kamiya Y; Takeyama Y; Mizuno T; Satoh F; Asanuma H
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32717920
[TBL] [Abstract][Full Text] [Related]
13. High potency silencing by single-stranded boranophosphate siRNA.
Hall AH; Wan J; Spesock A; Sergueeva Z; Shaw BR; Alexander KA
Nucleic Acids Res; 2006; 34(9):2773-81. PubMed ID: 16717282
[TBL] [Abstract][Full Text] [Related]
14. Terminal Duplex Stability and Nucleotide Identity Differentially Control siRNA Loading and Activity in RNA Interference.
Angart PA; Carlson RJ; Adu-Berchie K; Walton SP
Nucleic Acid Ther; 2016 Oct; 26(5):309-317. PubMed ID: 27399870
[TBL] [Abstract][Full Text] [Related]
15. Effects of Chemical Modifications on siRNA Strand Selection in Mammalian Cells.
Varley AJ; Hammill ML; Salim L; Desaulniers JP
Nucleic Acid Ther; 2020 Aug; 30(4):229-236. PubMed ID: 32175808
[TBL] [Abstract][Full Text] [Related]
16. Re-Engineering RNA Molecules into Therapeutic Agents.
Egli M; Manoharan M
Acc Chem Res; 2019 Apr; 52(4):1036-1047. PubMed ID: 30912917
[TBL] [Abstract][Full Text] [Related]
17. Probing the Binding Interactions between Chemically Modified siRNAs and Human Argonaute 2 Using Microsecond Molecular Dynamics Simulations.
Harikrishna S; Pradeepkumar PI
J Chem Inf Model; 2017 Apr; 57(4):883-896. PubMed ID: 28287733
[TBL] [Abstract][Full Text] [Related]
18. Differences in silencing of mismatched targets by sliced versus diced siRNAs.
Sun G; Wang J; Huang Y; Yuan CW; Zhang K; Hu S; Chen L; Lin RJ; Yen Y; Riggs AD
Nucleic Acids Res; 2018 Jul; 46(13):6806-6822. PubMed ID: 29718312
[TBL] [Abstract][Full Text] [Related]
19. Structurally modulated codelivery of siRNA and Argonaute 2 for enhanced RNA interference.
Li J; Wu C; Wang W; He Y; Elkayam E; Joshua-Tor L; Hammond PT
Proc Natl Acad Sci U S A; 2018 Mar; 115(12):E2696-E2705. PubMed ID: 29432194
[TBL] [Abstract][Full Text] [Related]
20. Loading of Argonaute Protein with Small Duplex RNA in Cellular Extracts.
Gagnon KT
Methods Mol Biol; 2016; 1421():53-67. PubMed ID: 26965257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
